Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 6/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 3/20 | 0.35 |
| ▸ | LSS | P48449 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | PRF1 | P14222 | 1/20 | 0.33 |
| ▸ | WRN | Q14191 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716228 | 0.73 | MCHR1 (0.43) | MCHR1LMNAKCNH2ITGB3ITGA2B | |
| SCHEMBL14705447 | 0.70 | KIF11 (0.52) | KIF11PRF1 | |
| SCHEMBL27961778 | 0.70 | KIF11 (0.52) | KIF11PRF1 | |
| SCHEMBL4846030 | 0.69 | MCHR1 (0.42) | MCHR1KCNH2 | |
| SCHEMBL14705469 | 0.68 | KIF11 (0.50) | KIF11PRF1WRN | |
| SCHEMBL25165734 | 0.67 | KIF11 (0.54) | KIF11PRF1 | |
| SCHEMBL27773425 | 0.66 | HDAC6 (0.48) | MCHR1HDAC4HDAC6 | |
| SCHEMBL5050187 | 0.66 | KIF11 (0.47) | LMNAKIF11PRF1WRN | |
| SCHEMBL14703090 | 0.66 | KIF11 (0.43) | KIF11PRF1WRN | |
| SCHEMBL8521914 | 0.66 | SNCA (0.52) | KIF11PRF1WRN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462620-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM, PLC (GB) | 2008-12-09 | — | — | US | disclosed |
| EP-1337517-B1 | PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2008-11-26 | — | — | EP | disclosed |
| US-7169924-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-01-30 | — | — | US | disclosed |
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | ELLIOTT RICHARD L | 2006-10-26 | — | — | US | disclosed |
| EP-1337517-A1 | PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002030911-A1 | PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | PLA2G7, PLA2G1B, PLA2G4B | MCHR1 4485/4885LMNA 410/4885KIF11 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.